Layer A — cited: COA practices, testing, enforcement, provenanceLayer B — disclaimed: online sentiment, community reportsIndependence firewall: the Trust Index (14/100) is computed from cited facts only — never sold, never sorts the directory.

V0 · V1 · V2 · V3 · V4

Overview

Independence-firewalled vendor profile · Trust Index computed from cited facts

GLP-1 Solution

glp1solution.storeDefunctResearch use only

US-facing research-peptide supplier. Identity and claims are vendor-stated unless cited. Research use only.

No verified badges yet

—products listed

—Trustpilot

—founded

Communityconfidence

2026-06-27 as of

Vendor Trust Index Flagged

14/100

Adverse Records on File

At least one verified disqualifying fact on record — e.g. an independently-measured purity misrepresentation and/or stacked enforcement and conduct records. Caution warranted.

Coverage43%

ConfidenceModerate

Cited facts9

A transparency readout of 9 cited facts — never sold, never sorts the directory; not a safety verdict (RUO). How it’s computed →

Catalog breadth

—

No data available

External rating

—

No data available

COA policy

Cited

None

none on record

Operating status

Cited

Defunct

as of 2026-06-27

Trust Index breakdown

DerivedV3

Five weighted evidence pillars; the composite is then capped by any verified adverse fact. Every point traces to a cited source — nothing here can be bought.

Claims vs. reality (purity integrity)0/30 · 30%

Testing & verification transparency0/20 · 20%

Regulatory & enforcement conduct8/20 · 20%

Operational transparency & accountability6/18 · 18%

Reputation integrity0/12 · 12%

Caps applied · a verified adverse fact ceilings the score

Active enforcement action — ceilinged at 49. An active, unresolved enforcement action is on record with no close-out or cited remediation.

Raw 14 → capped 14/100 · Moderate confidence · 43% coverage (5/12 evidence dimensions). Full methodology.

Evidence at a glance

DerivedV3

Products listed: No data available
Publishes COAs: No
Independent tests tracked: 0
Enforcement records: 1
Cited sources: 9

Methodology & independence

CitedV4

The Trust Index is computed only from cited facts — and can never be bought.
Sponsorship & affiliate are excluded by construction — they never move the score, sort, or inclusion.
Facts are dated and cited; absent data lowers confidence, never the score (absence isn’t evidence of bad).

No affiliate relationship with this vendor.

Legitimacy signals

DerivedV2

Official domain: glp1solution.store
Payment: Not disclosed
Third-party testing: Not confirmed
Published COAs: No
HQ disclosed: Not disclosed
Sponsored placement: No

Vendor details

CitedV1

Founded (claimed): No data available
HQ: DE
Address: 785 15th Street, Office 478, 81566 Berlin, Germany (as listed in the FDA warning letter; address appears internally inconsistent — see registration note)
Contact: sales@glp1solution.store
Ships from: No data available
Ships to: US
Categories: GLP-1 / Metabolics
Grade claimed: No data available
Website: glp1solution.store

WHOIS: The FDA warning letter lists the firm at '785 15th Street, Office 478, 81566 Berlin, Germany' with email sales@glp1solution.store. The address is internally inconsistent: '785 15th Street / Office 478' is a US-style street format, while the city (Berlin) and postal code (81566) do not match — German postal codes beginning 81xxx correspond to the Munich area, not Berlin (10xxx–14xxx). This suggests a possibly fabricated or obfuscated address typical of cross-border grey-market sellers. The original glp1solution.store domain has since lapsed and is now offered for resale, with no current WHOIS/founding data recoverable; expireddomains.com shows a December 2, 2025 date that postdates the warning letter and likely reflects a drop/re-registration rather than the original creation date. expireddomains.com

Find them

Verify you are on glp1solution.store — 2 domain variants exist; this is the one on record as current.

V5 · V6 · V7 · V8 · V9

Products & price

Pricing & listings are not in the seed yet — shipping facts are

Product catalog & pricelist

No data availablePrice-per-mg data has not been collected for this vendor.

Price-per-mg snapshot

No data availableNo price series collected.

Deals & bulk pricing

No data availableNo promotional or bulk pricing collected.

Price snapshot

No data availableRequires price data.

Shipping & fulfillment

CitedV9

Ships from: No data available
Ships to: US
Domestic shipping: No data available
Ship speed: No data available
Payment: No data available

Watch & alerts

V30

Status-change & enforcement alerts
Add to a comparison set

V10 · V11 · V12

Quality & COA verification

COA & testing practices

CitedV10

What this vendor proves about identity, purity & potency

Publishes COAs

not on record

Third-party tested

not on record

Independent tests tracked

not on record

GMP / ISO claim

not on record

No data available — no COA policy stated by this vendor.

COA repository · published lab results

No data availablePer-lot COA records have not been collected.

Independent test results

V11

No data availableNo independent assays tracked for this vendor.

Authenticity & anti-spoofing

CitedV12

Official domain: glp1solution.store

Only order from the official domain. Research-chem vendors are frequently impersonated by typosquats — verify the URL before purchase.

Known domain variants

glp1solution.store — official / defunct · The storefront the FDA reviewed in August 2025. As of 2026-06-27 the URL 301-redirects to expireddomains.com and the domain is listed for resale ('Buy Now', GoDaddy) — the original storefront is gone. Wayback shows it indexed in 2025 only.
glp1-solution.com — lookalike (separate, relationship unestablished) · A hyphenated near-identical name ('GLP 1 SOLUTION — Buy GLP-1 medications Now') presenting as a telehealth service as of 2026. No evidence ties it to the FDA-cited glp1solution.store; surfaced only to flag the naming collision, not asserted as the same operator.

V13 · V14 · V15 · V16 · V17

Reputation & sentiment

Online sentiment

Community signalUGC · disclaimedV13

Forum sentiment: unknown · unverified

A coarse community read, not a measured score. Platforms can be gamed — corroborate.

Reddit & community

UGC · disclaimedV14

No data availableCommunity mentions are not collected for this vendor.

Review sites

UGC · disclaimedV15

No data availableNo external ratings on file.

No Trustpilot profile, ScamAdviser entry, Reddit thread, peptide-forum review, or other independent reputation record for glp1solution.store could be found as of 2026-06-27. The only third-party coverage is the FDA warning letter and legal-firm analyses of the September 2025 GLP-1 enforcement sweep. The storefront domain now redirects to an expired-domain marketplace, so no live commerce or reputation footprint remains.

fda.gov

User reviews

Not collectedUGC · disclaimedV16

No data availableNo first-party reviews have been collected for this vendor.

Press & media

CitedV17

FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers

Wilson Sonsini Goodrich & Rosati · 2025-09

wsgr.com

FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers (mirror)

JD Supra · 2025-09

jdsupra.com

FDA ramps up crackdown on GLP-1 drug compounders with fresh batch of 30 warning letters

Fierce Pharma · 2025-09

fiercepharma.com

V18 · V19 · V20 · V21

Trust, risk & enforcement

Enforcement & legal history

CitedV18

Warning letters, raids, shutdowns, BBB actions — cited or omitted

FDA Warning Letter (MARCS-CMS 715883) to 'GLP-1 Solution' (listed at 785 15th Street, Office 478, 81566 Berlin, Germany; email sales@glp1solution.store) over the glp1solution.store website, which the FDA reviewed in August 2025 and found offered compounded retatrutide, semaglutide and tirzepatide. The compounded retatrutide products were deemed unapproved new drugs and misbranded drugs introduced into interstate commerce in violation of FD&C Act sections 505(a), 502(f)(1), 301(a) and 301(d); claims for the compounded semaglutide and tirzepatide were deemed false or misleading under sections 502(a) and 502(bb), violating section 301(a). Retatrutide is ineligible for compounding exemptions (no USP/NF monograph, not a component of an FDA-approved drug, not on the 503A bulks list). One of more than 50 GLP-1 warning letters the FDA issued in the September 2025 sweep, most dated 2025-09-09; legal analysis specifically cites GLP-1 Solution as an example of a foreign (Berlin, Germany) company targeted. As of 2026-06-27 no close-out letter was found and the storefront domain is offline.

2025-09-09 · fda warning · fda.gov

We publish negative records only with a source, and offer vendors a right of reply.

Buyer safety checklist

DerivedV19

Publishes COAs
Third-party tested
Accepts non-crypto payment
Has reship / refund policy
Clean enforcement record
Currently operating

1 of 6 checks clear · derived from vendor-stated data.

Operating status & continuity

CitedV20

Status: Defunct
Last confirmed: 2026-06-27
US-facing: Yes
Domain history: 2 variants on record
Known rebrands / aliases: None on record

The FDA warning letter lists the firm at '785 15th Street, Office 478, 81566 Berlin, Germany' with email sales@glp1solution.store. The address is internally inconsistent: '785 15th Street / Office 478' is a US-style street format, while the city (Berlin) and postal code (81566) do not match — German postal codes beginning 81xxx correspond to the Munich area, not Berlin (10xxx–14xxx). This suggests a possibly fabricated or obfuscated address typical of cross-border grey-market sellers. The original glp1solution.store domain has since lapsed and is now offered for resale, with no current WHOIS/founding data recoverable; expireddomains.com shows a December 2, 2025 date that postdates the warning letter and likely reflects a drop/re-registration rather than the original creation date.

Defunct: this vendor is no longer operating. Listing retained for reference and enforcement history. Do not attempt to purchase.

Scam & non-delivery reports

Community-reportedUGC · disclaimedV21

No data availableCommunity scam/non-delivery reports are not collected for this vendor.

V22 · V23 · V24

Compare & discover

Compare vendors

V22

See GLP-1 Solution side-by-side with every vendor on the directory — COA practices, testing, shipping, enforcement history.

Similar vendors

V23

No data availableSimilar-vendor matching is not yet computed.

Best value for

V24

Cross-vendor price ranking is intentionally not computed

The Trust Index rates each vendor against a fixed evidence rubric — it never ranks vendors against each otheror sorts the directory. Naming a “best-value” vendor per compound would require exactly that cross-vendor sort, so we don’t. Compare the cited price-per-mg in the Products & price table yourself, or open a side-by-side comparison.

V25 · V26 · V27 · V28 · V29 · V31

Compliance, meta & tools

Jurisdiction & legality

CitedV25

Ships to: US
US-facing: Yes
Gating: Commercial links suppress where a compound is restricted in your region

Commercial CTAs are jurisdiction-gated; reference content stays visible everywhere (RUO).

Independence & disclosure

CitedV26

Affiliate: No
Sponsored placement: None
Effect on Trust Index: None — sponsorship & affiliate are excluded by construction

No affiliate or sponsorship relationship on record.

Data confidence & provenance

CitedV27

Reviewed by: PeptideCompass editorial
Sources: 9 cited
Captured: 2026-06-27
Provenance: web_research + adversarial_verification

View 9 sources

FAQ

CitedV31

Is GLP-1 Solution still operating?

No. The glp1solution.store storefront — the site the FDA reviewed in August 2025 — is offline as of 2026-06-27; the domain now redirects to an expired-domain marketplace and is listed for resale. The operator received an FDA warning letter on September 9, 2025. Research use only.

expireddomains.com

What did the FDA say about GLP-1 Solution?

On September 9, 2025 the FDA issued warning letter MARCS-CMS 715883 to GLP-1 Solution (listed at a Berlin, Germany address) over the glp1solution.store website, which offered compounded retatrutide, semaglutide and tirzepatide. The FDA called the retatrutide products unapproved new drugs and misbranded drugs in violation of FD&C Act sections 505(a), 502(f)(1), 301(a) and 301(d), and called the semaglutide/tirzepatide claims false or misleading under sections 502(a) and 502(bb). It was one of more than 50 GLP-1 warning letters the FDA sent in that sweep. Research use only.

fda.gov

Citable summary (GEO)

DerivedV29

GLP-1 Solution (glp1solution.store) is a US-facing research-peptide vendor, now defunct (no longer operating). Has enforcement/disclosure records on file. PeptideCompass Trust Index: 14/100 — Adverse Records on File (flagged), moderate confidence, from 9 cited sources. Data is community and dated 2026-06-27. The Trust Index is an evidence-transparency readout of cited facts — not a safety verdict, never sold. Research use only.

JSON-LD: Organization · BreadcrumbList · FAQPage. Computed from cited facts, never sold.

Contribute, report & claim

V28

Reports are moderated · not verified by PeptideCompass